Editorial

The role of bioinformatics algorithms in modern biopharmaceutical design: Progress, challenges, and future perspectives

From sequence to structure to function: Algorithmic acceleration

The biological design space is combinatorial by nature; billions of possible variants emerge from even a small protein scaffold. Traditional high-throughput experimentation, while powerful, remains costly, time-consuming, and limited in scope. Algorithms close this gap through (i) sequence-structure prediction e.g., deep-learning (DL) structural models e.g., D-I-TASSER,¹ (ii) molecular docking and interaction scoring,¹ (iii) stability and solubility estimation under pharmaceutical constraints, (iv) immunogenicity and epitope assessments for therapeutic safety.²

The fusion of physics-based simulation with machine learning (ML) models allows us to traverse sequence landscapes with unprecedented accuracy. What once required a year of iterative assays can now occur in days through in silico screening.

AI-driven design: beyond predicting, toward inventing biology

Generative models such as variational autoencoders,³ diffusion models,⁴ and protein language models,⁵ have marked a significant shift in how biological design is approached. We no longer design by manual mutation; instead, we co-design with machines that learn evolutionary constraints and suggest novel therapeutic candidates. As practical examples, it should be mentioned that bioinformatics algorithms are actively driving real-world innovation across diverse classes of biopharmaceuticals. For instance, generative and predictive models are reshaping enzyme engineering by identifying mutations that improve catalytic efficiency in industrial and therapeutic pathways. In antibody development, DL–based affinity maturation can optimize both antigen-binding kinetics and manufacturability profiles early in the discovery pipeline, minimizing downstream redesign cycles. Vaccine design also benefits significantly from immunoinformatics frameworks capable of predicting conserved,⁶ multi-epitope antigens against rapidly evolving pathogens, thereby accelerating the transition from genomic surveillance to clinical candidate bio-drugs.⁷

Likewise, computational humanization and immunogenicity de-risking strategies assist in tailoring therapeutic proteins to patient-specific contexts, effectively reducing attrition caused by adverse immune responses.⁸ This ongoing transition from predictive analysis to algorithmic creativity represents one of the most notable advances in therapeutic bioinformatics to date. Looking forward, emerging hybrid frameworks that couple generative AI with physics-informed neural networks (PINNs) are poised to further enhance model accuracy and mechanistic interpretability, particularly in enzyme kinetics and catalytic pathway prediction.⁹ By embedding physical conservation laws within generative architectures, these hybrid systems overcome the limitations of purely data-driven models and enable more robust extrapolation to novel biochemical contexts. Recent applications of PINNs in biocatalysis and protein dynamics modeling have demonstrated improved reaction rate estimation and thermodynamic consistency compared to traditional ML approaches,¹⁰ positioning such methods as a promising direction for next-generation bioinformatics algorithms.

Systems-level design and multimodal data integration

Biopharmaceutical function is inherently multilayered. It implies that the linear sequence defines the structure, structure informs function, and ultimately cellular and immunological contexts determine therapeutic outcomes. To address this complexity, modern computational pipelines employ multi-omics integration algorithms such as feature-selection models that fuse transcriptomics, proteomics, and tumor-neoantigen profiles to prioritize more druggable and clinically actionable targets. Additionally, graph-based network inference techniques,¹¹ including protein interaction adaptive graph convolutional network (e.g., PF-AGCN¹²) and immune repertoire network modeling (e.g., NAIR¹³), help to decipher how therapeutic proteins interfere with cell signaling cascades or evade immune activation. Importantly, these algorithmic predictions do not remain static; adaptive ML frameworks, such as reinforcement learning-guided optimization or Bayesian active learning, iteratively update their models throughout in silico design–build–test cycles, as fresh biochemical and biophysical data are incorporated into the evaluation of therapeutic candidates. By converging heterogeneous biological layers into a unified computational interpretation, these methods yield far more reliable forecasts of clinical performance and manufacturability, enabling the early elimination of weak candidates well before costly pre-clinical development.

Manufacturability and developability: The often-ignored algorithmic frontier

Despite functional breakthroughs, an engineered therapeutic must still be (i) expressible at scale, (ii) stable during purification and storage, (iii) low-viscosity and aggregation-resistant in formulation, (iv) non-immunogenic in population-level diversity. Bioinformatics algorithms, for example, protein stability prediction using AlphaFold-Multimer¹⁴ or sequence optimization with RosettaDesign,¹⁵ increasingly incorporate such bioprocessability metrics early in the design stage. This prevents late-stage failures and aligns innovation with industrial feasibility.

Challenges: where algorithmic optimism meets biological reality

Despite great progress, several pressing limitations remain. First, sparse ground-truth data continues to restrict the reliability of AI-driven models, particularly in emerging therapeutic modalities such as bispecific antibodies,¹⁶ gene-editing enzymes,¹⁷ and de novo protein scaffolds,¹⁸ Unlike natural proteins with decades of accumulated structural, kinetic, and safety data, experimental annotations for these engineered entities are scarce, making models prone to overfitting and reduced real-world validity. This challenge is especially noted in enzyme engineering studies where only a tiny fraction of the mutational landscape has experimentally validated fitness measurements.

Second, interpretability and biophysical rigor remain critical barriers to clinical translation. Black-box neural networks may generate high-performing predictions, yet without mechanistic transparency regarding molecular stability, immunogenicity, or binding pathways, regulatory frameworks cannot confidently endorse algorithm-derived candidates for human use. Recent protein and antibody design pipelines¹⁹ suggest that models incorporating explicit structural or thermodynamic constraints, for example diffusion-based, physics-informed frameworks such as RFdiffusion¹⁸ can outperform purely sequence-based language models such as evolutionary scale modeling (ESM) on several structure, binding, and developability benchmarks.²⁰ Because these physics-informed models expose epitope:paratope interactions and stability features that map onto established biophysical criteria, they are also argued to be more amenable than purely statistical predictors to regulatory review and downstream manufacturability assessment.

Third, generalization across biological contexts is far from guaranteed. A therapeutic protein optimized in silico, for example, for high binding affinity in a specific host cell line, may exhibit drastically different properties in vivo due to variations in glycosylation, immune response, proteolysis, or microbiome interaction. Studies in mRNA vaccine optimization highlight this gap,^21-23 where constructs showing strong predicted translation efficiency occasionally underperform in diverse patient populations with distinct innate immune sensitivities.²⁴ Notably, early mRNA vaccine development efforts such as BioNTech’s initial trials demonstrated that aggressive codon optimization, while computationally favorable, could unexpectedly reduce protein expression or alter immune activation profiles, underscoring the need for experimentally guided sequence refinement alongside algorithmic design. Recent advances such as the LinearDesign algorithm²⁵ illustrate how jointly optimizing codon usage and structural stability can overcome such pitfalls, achieving markedly improved half-life and translation efficiency compared to traditional codon-optimization benchmarks.

Fourth, computational scalability is still a practical constraint. High-fidelity simulation methods such as long-timescale molecular dynamics or mixed quantum mechanics/molecular mechanics (QM/MM) calculations offer deeper insight into conformational behavior and catalytic mechanisms but remain compute-intensive, limiting their feasibility in early discovery cycles where thousands of variants must be evaluated.²⁶ Nevertheless, recent advances in structure prediction and molecular modeling such as AlphaFold 3,²⁷ OpenFold,²⁸ and NeuralPlexer,²⁹ have begun to alleviate these constraints by achieving near–QM-level accuracy with markedly improved scalability, enabling broader in silico screening and iterative design at reduced computational cost.

Ethical and biosecurity considerations demand parallel innovation in model governance. The same generative design tools capable of discovering novel antitumor cytokines or antibody therapeutics can, in theory, be misappropriated to engineer highly virulent proteins or evade immunological detection. Accordingly, leading organizations are now advocating standardized transparency, access control, and safety guardrails to ensure that algorithmic advancements in biopharmaceuticals remain aligned with global health priorities.

From a translational and regulatory standpoint, agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have begun articulating frameworks for the oversight of AI/ML-derived therapeutics, as highlighted in the FDA 2025 discussion paper on artificial intelligence in drug development. These initiatives emphasize the need for traceability, algorithmic interpretability, and model lifecycle management. Incorporating these governance principles into algorithmic pipelines can not only facilitate regulatory approval but also strengthen clinical confidence in AI-driven discovery, bridging the current divide between innovation and implementation.

Looking ahead: Human-algorithm collaboration

The future of biopharmaceutical innovation will be shaped by a paradigm in which human expertise and algorithmic intelligence operate as co-architects rather than counterparts. Cross-disciplinary fluency is no longer a desirable skill but an operational necessity: researchers must simultaneously wield advanced computational literacy, encompassing algorithm design, biostatistical robustness, and model reliability and deep molecular and pharmacological insight to contextualize predictions within biological and clinical reality. The role of computation is not to replace biological experimentation, but to transform it into an iterative, data-driven feedback system.

In this emerging framework, experimental measurements continuously recalibrate ML models; those models, in turn, generate novel design hypotheses and prioritize candidates with the highest prospects for therapeutic success; subsequent targeted validation enriches the collective knowledge base, further improving algorithmic accuracy. Such a closed-loop design–build–test–learn ecosystem, powered by scalable simulation, adaptive learning, and mechanistic interpretation, will catalyze more rapid and precise development of next-generation therapeutics. Ultimately, the most transformative breakthroughs will come from seamlessly integrating human intuition with computational optimization, where algorithms become intelligent partners in discovering and engineering the medicines of tomorrow.

Conclusion

Bioinformatics algorithms have evolved into strategic engines of therapeutic discovery, compressing timelines, reducing costs, and unlocking biological territories once inaccessible to experimental science alone. Yet, as we stand at this inflection point, we must maintain rigor, transparency, and interdisciplinary alignment to ensure responsible, clinically impactful innovation. The future of biopharmaceutical design will belong to those who not only understand biology and computation independently, but can engineer the interface between them.

Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Data Availability Statement

This editorial does not include new experimental data or proprietary datasets. All information discussed is derived from publicly available literature, computational frameworks, and previously published resources cited within the text. No new data were generated or analyzed in support of this article. Therefore, data sharing is not applicable to this work.

Declaration of AI-assisted Tools in the Writing Procedure

During the preparation of this work, the authors used ChatGPT version 5.1 (OpenAI) to assist with paraphrasing portions of the manuscript and to check the grammar of the translations from Persian into English. After using these tools, the authors thoroughly reviewed, edited, and verified the content and take full responsibility for the accuracy and integrity of the publication.

Ethical Approval

We extend our appreciation to the Ethics Committee of Tabriz University of Medical Sciences for granting ethical approval for this study (Ethical Code: IR.TBZMED.REC.1402.769).

References

1. Zhou X, Zheng W, Li Y, Pearce R, Zhang C, Bell EW. I-TASSER-MTD: a deep-learning-based platform for multi-domain protein structure and function prediction. Nat Protoc 2022; 17:2326-53. doi: 10.1038/s41596-022-00728-0 [Crossref] [ Google Scholar]
2. Guo J, Jia Z, Yang Y, Wang N, Xue Y, Xiao L. Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis. Int Immunopharmacol 2025; 152:114415. doi: 10.1016/j.intimp.2025.114415 [Crossref] [ Google Scholar]
3. Ochiai T, Inukai T, Akiyama M, Furui K, Ohue M, Matsumori N. Variational autoencoder-based chemical latent space for large molecular structures with 3D complexity. Commun Chem 2023; 6:249. doi: 10.1038/s42004-023-01054-6 [Crossref] [ Google Scholar]
4. Alakhdar A, Poczos B, Washburn N. Diffusion models in de novo drug design. J Chem Inf Model 2024; 64:7238-56. doi: 10.1021/acs.jcim.4c01107 [Crossref] [ Google Scholar]
5. Lam HY, Guan JS, Ong XE, Pincket R, Mu Y. Protein language models are performant in structure-free virtual screening. Brief Bioinform 2024; 25:bbae480. doi: 10.1093/bib/bbae480 [Crossref] [ Google Scholar]
6. Salemi A, Pourseif MM, Masoudi-Sobhanzadeh Y, Ansari R, Omidi Y. Proteome-wide reverse vaccinology to identify potential vaccine candidates against Staphylococcus aureus. Mol Immunol 2025; 183:296-312. doi: 10.1016/j.molimm.2025.05.016 [Crossref] [ Google Scholar]
7. Majidiani H, Pourseif MM, Kordi B, Sadeghi MR, Najafi A. TgVax452, an epitope-based candidate vaccine targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence (SRS) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches. BMC Infect Dis 2024; 24:886. doi: 10.1186/s12879-024-09807-x [Crossref] [ Google Scholar]
8. Ebrahimi SB, Samanta D. Engineering protein-based therapeutics through structural and chemical design. Nat Commun 2023. 14: 2411. doi: 10.1038/s41467-023-38039-x.
9. Wang Z, Xie D, Wu D, Luo X, Wang S, Li Y, et al. Robust enzyme discovery and engineering with deep learning using CataPro. Nat Commun 2025. 16: 2736. doi: 10.1038/s41467-025-58038-4.
10. Omar SI, Keasar C, Ben-Sasson AJ, Haber E. Protein design using physics informed neural networks. Biomolecules 2023. 13: 457. doi: 10.3390/biom13030457.
11. Que J, Xue G, Wang T, Jin X, Wang Z, Cai Y, et al. Identifying T cell antigen at the atomic level with graph convolutional network. Nat Commun 2025. 16: 5171. doi: 10.1038/s41467-025-60461-6.
12. Yang S, Su Y, Lin Y, Lin Q, Chen Z. PF-AGCN: an adaptive graph convolutional network for protein-protein interaction-based function prediction. Bioinformatics 2025. 41: btaf473. doi: 10.1093/bioinformatics/btaf473.
13. Yang H, Cham J, Neal BP, Fan Z, He T, Zhang L. NAIR: network analysis of immune repertoire. Front Immunol 2023. 14: 1181825. doi: 10.3389/fimmu.2023.1181825.
14. Kim AR, Hu Y, Comjean A, Rodiger J, Mohr SE, Perrimon N. Enhanced protein-protein interaction discovery via AlphaFold-Multimer. bioRxiv [Preprint]. February 21, 2024. Available from: https://www.biorxiv.org/content/10.1101/2024.02.19.580970v1.
15. Liu Y, Kuhlman B. RosettaDesign server for protein design. Nucleic Acids Res 2006. 34: W235-8. doi: 10.1093/nar/gkl163.
16. Shadman M, Gopal AK. Bispecific antibodies in action: the reality of engagement. Blood 2025. 146: 2148-50. doi: 10.1182/blood.2025030376.
17. Yin Y, Wang Q, Xiao L, Wang F, Song Z, Zhou C, et al. Advances in the engineering of the gene editing enzymes and the genomes: understanding and handling the off-target effects of CRISPR/Cas9. J Biomed Nanotechnol 2018. 14: 456-76. doi: 10.1166/jbn.2018.2537.
18. Watson JL, Juergens D, Bennett NR, Trippe BL, Yim J, Eisenach HE, et al. De novo design of protein structure and function with RFdiffusion. Nature 2023. 620: 1089-100. doi: 10.1038/s41586-023-06415-8.
19. Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 2025. doi: 10.1038/s41586-025-09721-5.
20. Zhang Q, Chen W, Qin M, Wang Y, Pu Z, Ding K, et al. Integrating protein language models and automatic biofoundry for enhanced protein evolution. Nat Commun 2025. 16: 1553. doi: 10.1038/s41467-025-56751-8.
21. Pourseif MM, Parvizpour S, Jafari B, Dehghani J, Naghili B, Omidi Y. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines. Bioimpacts 2021. 11: 65-84. doi: 10.34172/bi.2021.11.
22. Pourseif MM, Masoudi-Sobhanzadeh Y, Azari E, Parvizpour S, Barar J, Ansari R, et al. Self-amplifying mRNA vaccines: mode of action, design, development and optimization. Drug Discov Today 2022. 27: 103341. doi: 10.1016/j.drudis.2022.103341.
23. Omidi Y, Pourseif MM, Ansari RA, Barar J. Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations. Nanomedicine (Lond) 2024. 19: 2699-725. doi: 10.1080/17435889.2024.2419815.
24. Panigaj M, Basu Roy T, Skelly E, Chandler MR, Wang J, Ekambaram S, et al. Autonomous nucleic acid and protein nanocomputing agents engineered to operate in living cells. ACS Nano 2025. 19: 1865-83. doi: 10.1021/acsnano.4c13663.
25. Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 2023; 621:396-403. doi: 10.1038/s41586-023-06127-z [Crossref] [ Google Scholar]
26. Brunk E, Rothlisberger U. Mixed quantum mechanical/molecular mechanical molecular dynamics simulations of biological systems in ground and electronically excited states. Chem Rev 2015. 115: 6217-63. doi: 10.1021/cr500628b.
27. Fang Z, Ran H, Zhang Y, Chen C, Lin P, Zhang X, et al. AlphaFold 3: an unprecedent opportunity for fundamental research and drug development. Precis Clin Med 2025. 8: pbaf015. doi: 10.1093/pcmedi/pbaf015.
28. Ahdritz G, Bouatta N, Floristean C, Kadyan S, Xia Q, Gerecke W, et al. OpenFold: retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization. Nat Methods 2024. 21: 1514-24. doi: 10.1038/s41592-024-02272-z.
29. Qiao Z, Nie W, Vahdat A, Miller TF, Anandkumar A. State-specific protein-ligand complex structure prediction with a multiscale deep generative model. Nat Mach Intell 2024. 6: 195-208. doi: 10.1038/s42256-024-00792-z.